Multidisciplinary approach of colorectal liver metastases

Clinical and Translational Oncology

Volumn 13, Issue 10, 2011, Pages 721-727

  Juez, Ignacio ^a   Rubio, Carmen ^b   Figueras, Joan ^c  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b Hospital Universitario Madrid Sanchinarro   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Chemotherapy; Colorectal liver metastases; Radiotherapy; Surgery

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADVANCED CANCER; ARTICLE; BCL2 GENE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CDKN1A GENE; CHEMORADIOTHERAPY; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; DIHYDROPYRIMIDINE DEHYDROGENASE GENE; DISEASE FREE SURVIVAL; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RESPONSE; FATTY LIVER; HUMAN; ICE GENE; INTERMETHOD COMPARISON; LIVER INJURY; LIVER METASTASIS; LIVER RESECTION; MULTIPLE CYCLE TREATMENT; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; P219 GENE; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION INJURY; RISK ASSESSMENT; RISK FACTOR; STEATOSIS; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; THYMIDYLATE SYNTHETASE GENE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; RADIOTHERAPY;

EID: 81255165929     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0722-x     Document Type: Article

References (64)

1. -(2010) Area de Epidemiología ambiental y Cáncer, Centro Nacional de Epidemiología, Instituto de Salud Carlos III. La situación del Cáncer en España 1975-2006. http://www.isciii.es
2. R. Adam V. Delvart G. Pascal, et al. 2004 Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival Ann Surg 240 644 658 15383792 10.1097/01.sla.0000145964. 08365.01 (Pubitemid 39602132)
3. R. Goldberg M. Rothenberg E. Van Cutsem, et al. 2007 The continuum of care: a paradigm for the management of metastasic colorectal cancer Oncologist 12 38 50 17227899 10.1634/theoncologist.12-1-38 (Pubitemid 46143501)
4. B. Nordlinger M. Guiguet J.C. Vaillant, et al. 1996 Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie Cancer 77 1254 1262 8608500 10.1002/(SICI)1097-0142(19960401)77: 7<1254::AID-CNCR5>3.0.CO;2-I 1:STN:280:DyaK287pslCiuw%3D%3D (Pubitemid 26102322)
5. Y. Fong J. Fortner R.L. Sun, et al. 1999 Clinical score for predicting recurrence after hepatic resection for metastasic colorectal cancer: analysis of 1001 consecutive cases Ann Surg 230 309 318 10493478 10.1097/00000658- 199909000-00004 1:STN:280:DyaK1MvitFahsw%3D%3D (Pubitemid 30191861)
6. J. Figueras C. Valls A. Rafecas, et al. 2001 Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases Br J Surg 88 980 985 11442531 10.1046/j.0007-1323.2001.01821.x 1:STN:280:DC%2BD3MzovVOkug%3D%3D (Pubitemid 34015581)
7. C.H. Köhne D. Cunningham C.F. Di, et al. 2002 Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastasic colorectal cancer: results of a multivariate analysis of 3825 patients Ann Oncol 13 308 317 11886010 10.1093/annonc/mdf034 (Pubitemid 34704985)
8. P.C. Simmonds J.N. Primrose G.J. Poston, et al. 2006 Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies Br J Cancer 94 982 999 16538219 10.1038/sj.bjc.6603033 1:STN:280:DC%2BD287pt1altw%3D%3D
9. J.S. Tomlinson W.R. Jarnaguin R.P. De Matteo, et al. 2007 Actual 10-year survival after resection of colorectal liver metastases defines cure J Clin Oncol 25 4575 4580 17925551 10.1200/JCO.2007.11.0833 (Pubitemid 350035315)
10. B. Nordlinger E. Van Cutsem T. Gruenberger, et al. 2009 Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Ann Oncol 20 985 992 19153115 10.1093/annonc/mdn735 1:STN:280: DC%2BD1MzmvFyjtg%3D%3D
11. B. Gruenberger W. Scheithauer R. Punzengruber, et al. 2008 Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases BMC Cancer 8 120 18439246 10.1186/1471-2407-8-120 (Pubitemid 351715876)
12. B. Nordlinger H. Sorbye B. Glimelius, et al. 2008 Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial Lancet 371 1007 1016 18358928 10.1016/S0140-6736(08)60455-9 1:CAS:528:DC%2BD1cXjs1Sltbg%3D (Pubitemid 351392040)
13. Y. Nakajima M. Nagao S. Ko, et al. 2001 Clinical predictors of recurrence site after hepatectomy for metastasic colorectal cancer Hepatogastroenterology 48 1680 1684 11813600 1:STN:280:DC%2BD38%2Fos1eitA%3D%3D (Pubitemid 34003503)
14. N.J. Petrelli 2008 Perioperative or adjuvant therapy for resectable colorectal hepatic metastases J Clin Oncol 26 4862 4863 18794535 10.1200/JCO.2008.18.5868
15. B. Langer H. Blieberg R. Labianca, et al. 2002 Fluorouracil plus leucovorin versus observation after potentially curative resection of liver o lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVo) randomized trial Proc Am Soc Clin Oncol 21 149a
16. G. Portier D. Elias O. Bouche, et al. 2006 Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal lever metastases: FFCD ACHBTH AURC 9002 trial J Clin Oncol 24 4976 4982 17075115 10.1200/JCO.2006.06.8353 1:CAS:528: DC%2BD28Xht1GnurzP (Pubitemid 46631399)
17. E. Mitry A.L. Fields H. Bleiberg, et al. 2008 Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials J Clin Oncol 26 4906 4911 18794541 10.1200/JCO.2008.17.3781 1:CAS:528:DC%2BD1cXhtlGitrzJ
18. M. Ychou W. Hohenberger S. Thezenas, et al. 2009 A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer Ann Oncol 20 1964 1970 19567451 10.1093/annonc/mdp236 1:STN:280: DC%2BD1MjntFKqsw%3D%3D
19. R. Parks M. Gonen N. Kemeny, et al. 2007 Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents J Am Coll Surg 204 753 761 17481478 10.1016/j.jamcollsurg.2006. 12.036 (Pubitemid 46661187)
20. House MG, Kemeny N, Jarnigin W et al (2009) Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastasic colorectal cancer. In: American Society of Clinical Oncology - Gastrointestinal Cancer Symposium
21. R. Adam V. Delvart G. Pascal, et al. 2004 Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival Ann Surg 240 644 657 15383792 10.1097/01.sla.0000145964. 08365.01 (Pubitemid 39602132)
22. C. Barone G. Nuzzo A. Cassano, et al. 2007 Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases Br J Cancer 97 1035 1039 17895897 10.1038/sj.bjc.6603988 1:CAS:528:DC%2BD2sXhtFKktb%2FL (Pubitemid 47587006)
23. C. Pozzo M. Basso A. Cassano, et al. 2004 Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients Ann Oncol 15 933 939 15151951 10.1093/annonc/ mdh217 1:STN:280:DC%2BD2c3lt12jsQ%3D%3D (Pubitemid 39004350)
24. G. Masi S. Cupini L. Marcucci, et al. 2006 Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastasic colorectal cancer Ann Surg Oncol 13 58 65 16372158 10.1245/ASO.2006.03.094 (Pubitemid 43117646)
25. A. Lievre J.B. Bachet C.D. Le, et al. 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992 3995 16618717 10.1158/0008-5472.CAN-06-0191 1:CAS:528:DC%2BD28XjsFSlsb0%3D
26. R.G. Amado M. Wolf M. Peetres, et al. 2008 Wild type KRAS is required for panitumumab efficacy in patients with metastasic colorectal cancer J Clin Oncol 26 1626 1634 18316791 10.1200/JCO.2007.14.7116 1:CAS:528:DC%2BD1cXltlWhsrw%3D
27. R. Wong D. Cunningham 2008 Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies J Clin Oncol 26 5668 5770 19001346 10.1200/JCO.2008.19.5024 1:CAS:528:DC%2BD1MXotFemsg%3D%3D
28. C. Aschele D. Debernardis S. Casazza, et al. 1999 Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracilbased chemotherapy J Clin Oncol 17 1760 1770 10561213 1:CAS:528:DyaK1MXktV2qtLY%3D (Pubitemid 29269245)
29. D. Salonga K.D. Danenberg M. Johnson, et al. 2000 Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin Cancer Res 6 1332 1337
30. S. Iqbal H.J. Lenz 2003 Molecular predictors of treatment and outcome in colorectal cancer Curr Gastroenterol Rep 5 399 405 12959721 10.1007/s11894-003- 0053-3 (Pubitemid 38899282)
31. J. Stoehlmacher D.J. Park W. Zhang, et al. 2004 A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer Br J Cancer 91 344 354 15213713 1:CAS:528:DC%2BD2cXls1eht7o%3D (Pubitemid 39037082)
32. G. Folprecht A. Grothey S. Alberts, et al. 2005 Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumor response and resection rates Ann Oncol 16 1311 1319 15870084 10.1093/annonc/mdi246 1:STN:280:DC%2BD2MzotFamsA%3D%3D (Pubitemid 41158476)
33. C. Tournigand T. Andre E. Achille, et al. 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 229 237 14657227 10.1200/JCO.2004.05.113 1:CAS:528:DC%2BD2cXpsVKit7w%3D (Pubitemid 41095086)
34. R.M. Goldberg D.J. Sargent R.F. Morton, et al. 2004 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 23 30 14665611 10.1200/JCO.2004.09.046 1:CAS:528: DC%2BD2cXpsVKitbY%3D (Pubitemid 41095110)
35. A. Falcone S. Ricci I. Brunetti, et al. 2007 Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 1670 1676 17470860 10.1200/JCO.2006.09.0928 1:CAS:528:DC%2BD2sXlvFyktb8%3D (Pubitemid 46797946)
36. J. Souglakos N. Androulakis K. Syrigos, et al. 2006 FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first line treatment in metastasic colorectal cancer: a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG) Br J Cancer 94 798 805 16508637 10.1038/sj.bjc.6603011 1:CAS:528:DC%2BD28Xis1GktL0%3D
37. L.B. Saltz S. Clarke E. Diaz-Rubio, et al. 2008 Bevacizumab in combination with oxaliplatinbased chemotherapy as first line therapy in metastasic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019 18421054 10.1200/JCO.2007.14.9930 1:CAS:528:DC%2BD1cXlvFaqs7g%3D
38. A. Okines O.D. Puerto D. Cunningham, et al. 2009 Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastasic colorectal cancer First BEAT and the randomized phase-III NO 16966 trial Br J Cancer 101 1033 1038 19789532 10.1038/sj.bjc. 6605259 1:CAS:528:DC%2BD1MXhtF2lu7rL
39. B. Gruenberger D. Tamandl J. Schueller, et al. 2008 Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastasic colorectal cancer J Clin Oncol 26 1830 1835 18398148 10.1200/JCO.2007.13.7679 1:CAS:528:DC%2BD1cXmsFemsbg%3D
40. G. Folprecht T. Gruenberger W.O. Bechstein, et al. 2010 Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomized phase II trial Lancet Oncol 11 38 47 19942479 10.1016/S1470-2045(09)70330-4 1:CAS:528:DC%2BC3cXjslKrsA%3D%3D
41. E. Van Cutsem C.H. Kohne E. Hitre, et al. 2009 Cetuximab and chemotherapy as initial treatment for metastasic colorectal cancer N Engl J Med 360 1408 1417 19339720 10.1056/NEJMoa0805019
42. J.Y. Douillard S. Siena J. Cassidy, et al. 2010 Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 4697 4705 20921465 10.1200/JCO.2009.27.4860 1:CAS:528:DC%2BC3cXhsF2rtLzI
43. Tveit K, Guren T, Glimelius P et al (2011) Oral abstract Session (#A10). Gastrointestinal Cancer Symposium. January 20-22
44. T. Maughan R. Adams C. Smith, et al. 2011 Addition of cetuximab to oxaliplatin-based firstline combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2103 2114 21641636 10.1016/S0140-6736(11)60613-2 1:CAS:528:DC%2BC3MXnslShtLk%3D
45. D. Zorzi A. Laurent T.M. Pawlik, et al. 2007 Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases Br J Surg 94 274 286 17315288 10.1002/bjs.5719 1:CAS:528:DC%2BD2sXkt12nt7s%3D (Pubitemid 46423843)
46. J.N. Vauthey T.M. Pawlik D. Ribero, et al. 2006 Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases J Clin Oncol 24 2065 2076 16648507 10.1200/JCO.2005.05.3074 1:CAS:528:DC%2BD28Xlt1amurY%3D (Pubitemid 46622116)
47. F.A. Scappaticci L. Feherenbacher T. Cartwright, et al. 2005 Surgical wound healing complications in metastasic colorectal cancer patients treated with bevacizumab J Surg Oncol 91 173 180 16118771 10.1002/jso.20301 1:CAS:528:DC%2BD2MXhtVGltrnK (Pubitemid 41254420)
48. D. Ribero H. Wang M. Donadon, et al. 2007 Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases Cancer 110 2761 2767 17960603 10.1002/cncr.23099 (Pubitemid 350250347)
49. H. Nakano E. Oussoultzoglou E. Rosso, et al. 2008 Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy Ann Surg 247 118 124 18156931 10.1097/SLA.0b013e31815774de
50. M. Karoui C. Penna M. Amin-Hashem, et al. 2006 Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases Ann Surg 243 1 7 16371728 10.1097/01.sla.0000193603.26265.c3 (Pubitemid 43054046)
51. R.R. White L.H. Schwartz J.A. Muñoz, et al. 2008 Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases J Surg Oncol 97 601 604 18449915 10.1002/jso.21042 (Pubitemid 351794150)
52. F.K. Welsh H.S. Tilney P.P. Tekkis, et al. 2007 Safe liver resection following chemotherapy for colorectal metastases is a matter of timing Br J Cancer 96 1037 1042 17353923 10.1038/sj.bjc.6603670 1:STN:280: DC%2BD2s3gt12jtA%3D%3D (Pubitemid 46608314)
53. R. Adam G. Pascal D. Castaing, et al. 2004 Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240 1052 1061 15570210 10.1097/01.sla.0000145964.08365.01 (Pubitemid 39602132)
54. D.J. Gallaguer J. Zheng M. Capanu, et al. 2009 Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases Ann Surg Oncol 16 1844 1851 10.1245/s10434-009- 0348-1
55. L.A. Dawson D. Normolle J.M. Balter 2002 Analysis of radiation-induced liver disease using the Lyman NTCP model Int J Radiat Oncol Biol Phys 53 4 810 821 12095546 10.1016/S0360-3016(02)02846-8 (Pubitemid 34722625)
56. L. Potters M. Steinberg C. Rose, et al. 2004 American Society of Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy Int J Radiat Oncol Biol Phys 60 1026 1032 15519771 10.1016/j.ijrobp.2004.06.114 (Pubitemid 39440785)
57. S.H. Benedict K.M. Yenice D. Followill, et al. 2010 Stereotactic body radiation therapy: the report of AAPM Task Group 101 Med Phys 37 4078 4101 20879569 10.1118/1.3438081
58. L.I. Blomgren I. Naslund R. Svanstrom, et al. 1994 Stereotactic radiotherapy of extracraneal targets Z Med Phys 4 112 113
59. K.K. Herfarth J. Debus F. Lohr, et al. 2001 Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial J Clin Oncol 19 164 170 11134209 1:STN:280:DC%2BD38%2Fgs1Sgsg%3D%3D (Pubitemid 32063493)
60. M.T. Milano A.W. Katz A.G. Mush, et al. 2008 A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastasic lesions Cancer 112 650 658 18072260 10.1002/cncr.23209 (Pubitemid 351186206)
61. A.W. Katz M. Carey-Sampson A.G. Muhs 2007 Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases Int J Radiat Oncol Biol Phys 67 793 798 17197128 10.1016/j.ijrobp.2006.10.025 (Pubitemid 46215888)
62. K.E. Rusthoven B.D. Kavanagh H. Cardenes 2009 Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases J Clin Oncol 27 1572 1578 19255321 10.1200/JCO.2008.19.6329
63. S. Stintzing R.T. Hoffmann V. Heinemann 2010 Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients Eur J Cancer 46 1026 1032 20153959 10.1016/j.ejca.2010.01.008 1:STN:280: DC%2BC3c3gvFSjsg%3D%3D
64. M.C. Rubio O. Hernando E. Sánchez 2011 Clinical experience on the treatment of lung and liver lesions with SBRT using a Novalis exactrac adaptive gating technique Clin Oncol 23 S1 S58 10.1016/j.clon.2011.01.352